What Ionis Pharmaceuticals (IONS) Said on Its Q3 Earnings Call

Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drug

Ionis Pharmaceuticals lost more than $1 billion in market value on Monday after the company slashed sales projections for a triglyceride-lowering drug the biotech and Wall Street analysts believe is a potential blockbuster.  The firm announced that it expects the drug, Tryngolza, to bring in $50 million in sales by the end of this year, compared to Ionis’ previous forecast of $100 to $110 million. Third quarter sales came in at $9 million, well …

Ionis (IONS) Q3 2026 Earnings Call Transcript

Launch ramp slows and cash flow breakeven shifts a year to 2029.

What Ionis Pharmaceuticals (IONS) Said on Its Q3 Earnings Call

Ionis Pharmaceuticals (NASDAQ:IONS) lowered its 2026 sales forecast for TRYNGOLZA after a slower-than-expected launch in severe hypertriglyceridemia, while pushing its target for sustained positive cash flow back by a year. The biotechnology company now expects approximately $50 million in full-yea

Ionis reports third quarter 2026 financial results and highlights progress on key programs

CARLSBAD, Calif.--(BUSINESS WIRE)--Nov 9, 2026-

Arrowhead Stock Tumbles 15% on Same Day Rival Ionis Cuts Tryngolza Forecast in Triglyceride Drug Market

Arrowhead Pharmaceuticals shares dropped 15.4% after rival Ionis sharply reduced its Tryngolza sales forecast, raising concerns about demand and the pace of growth in the severe hypertriglyceridaemia market.

Why Ionis (IONS) Stock Crashed Monday Even After Beating Earnings

TLDR Ionis (IONS) stock fell about 28% to $28.15 on Monday, its worst day since May 2016. The company cut its 2026 Tryngolza sales outlook to about $50 million from $100 million to $110 million. Third-quarter revenue hit $243 million, well above the $178.2 million analysts expected. Full-year revenue guidance of $875 million to $900 [...]